|
Preferred term
|
Study treatment period
|
|---|
|
1–8 weeks
|
9–24 weeks
|
>24 weeks
|
|---|
|
# of subjects continuing treatment, n (%)
|
82 (100)
|
58 (100)
|
23 (100)
|
|
Thrombocytopenia
|
70 (85.4)
|
42 (72.4)
|
18 (78.3)
|
|
Nausea/vomiting
|
68 (82.9)
|
21 (36.2)
|
5 (21.7)
|
|
Fatigue/asthenia
|
58 (70.7)
|
15 (25.9)
|
5 (21.7)
|
|
Neutropenia/febrile neutropenia
|
54 (65.9)
|
34 (58.6)
|
10 (43.5)
|
|
Hyponatremia
|
52 (63.4)
|
18 (31.0)
|
6 (26.1)
|
|
Decreased appetite
|
46 (56.1)
|
16 (27.6)
|
8 (34.8)
|
|
Weight decreased
|
44 (53.7)
|
27 (46.6)
|
7 (30.4)
|
|
Neurotoxicity
|
24 (29.3)
|
7 (12.1)
|
1 (4.3)
|
|
Diarrhea
|
22 (26.8)
|
7 (12.1)
|
1 (4.3)
|
|
Pneumonia
|
20 (24.4)
|
7 (12.1)
|
3 (13.0)
|
|
Vision blurred
|
5 (6.1)
|
2 (3.4)
|
2 (8.7)
|
|
Cataract
|
1 (1.2)
|
1 (1.7)
|
1 (4.3)
|
